Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JRF101 + PD-1 inhibitor
- Development stage
- Unknown
- Lead developer
- Shenzhen Jinruijiye Biotechnology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
JRF101 + PD-1 inhibitor is a combination therapy being developed by Shenzhen Jinruijiye Biotechnology for the treatment of solid tumors. The regimen consists of JRF101, an investigational small molecule, administered in conjunction with a monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor. JRF101 is part of a pipeline focused on small molecule treatments for brain and solid tumors, while the addition of a PD-1 inhibitor is intended to enhance the immune system's ability to identify and destroy cancer cells by blocking the PD-1/PD-L1 checkpoint pathway. This combination aims to leverage potential synergistic effects between the small molecule's mechanism and immune checkpoint blockade. As of 2024, the combination is in Phase 1/2 clinical development.
- Other names
- JRF101 + PD-1 inhibitor
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on JRF101 + PD-1 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JRF101 + PD-1 inhibitor.